Search Result

Results for "

HLA-DR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) CD28 (1) CD47 (1) IFNAR (2) Insulin Receptor (1) Interleukin Related (1) LAG-3 (1) MAP4K (1) MHC (1) STING (1) TNF Receptor (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (6) Inflammation/Immunology (6) Metabolic Disease (1)
Oligonucleotides:	CpG ODNs (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Antibodies

Oligonucleotides

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990189

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC	Others
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MHC class II.

HY-150749A

ODN D-SL03 sodium	IFNAR	Cancer
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150740A

ODN 21595 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

HY-P1901

Insulin alpha-chain (1-13)	Insulin Receptor	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-159123

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-150749

ODN D-SL03	IFNAR	Inflammation/Immunology Cancer
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with *HLA-DR* (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

HY-168384

M04	STING TNF Receptor Interleukin Related CD28	Inflammation/Immunology
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .

Cat. No.	Product Name	Target	Research Area

HY-P2507

NY-ESO-1 (87-111)	Peptides	Cancer
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 ⁺ T cells when presented in the context of HLA-DR and HLA-DP4 molecules .

HY-P1901

Insulin alpha-chain (1-13)	Insulin Receptor	Metabolic Disease
Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P10835

LAG-3 cyclic peptide inhibitor C25	LAG-3	Cancer
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a K_d value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with *HLA-DR* (MHC-II) and activate CD8 ⁺ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .

Cat. No.	Product Name	Target	Research Area

HY-P990189

*Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)*	MHC	Others
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MHC class II.

HY-P990606

IMMU-114	Inhibitory Antibodies	Inflammation/Immunology
IMMU-114 is a CHO expressed humanized antibody that targets *HLA-DR*. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P991366

IBI-397 AL008	CD47	Cancer
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83339

	HLA DR Antibody (YA3084) MLRW; HLA-DRA1; MHC class II antigen DRA; HLA class II histocompatibility antigen; DR alpha chain	WB, IHC-P, ICC/IF, FC	Human
	HLA DR Antibody (YA3084) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3084), targeting HLA DR, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). HLA DR Antibody (YA3084) can be used for WB, IHC-P, ICC/IF, FC experiment in human background.

HY-P81537

	CD74 Antibody (YA1282) CD74; DHLAG; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD74	IHC-P	Human
	CD74 Antibody (YA1282) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1282), targeting CD74. CD74 Antibody (YA1282) can be used for IHC-P experiment in human background.

HY-P85015

	HLA-DRA Antibody (YA4707) DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_HUMAN antibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen HLA DR alpha antibody; Histocompatibility antigen HLA-DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DR histocompatibility type antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody; HLA-DRA nanobody	ELISA	Human
	HLA-DRA Antibody (YA4707) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HLA-DRA. It can be applicated for ELISA assays, in the background of human.

HY-P83917

	HLA-DRB1 Antibody (YA3614) SS1; DRB1; HLA-DRB; HLA-DR1B	WB, IHC-P, FC, ELISA	Human
	HLA-DRB1 Antibody (YA3614) is a mouse-derived and non-conjugated IgG1 antibody, targeting to HLA-DRB1. It can be applicated for WB, IHC-P, FC, ELISA assays, in the background of human.

HY-P85007

	CD74 Antibody (YA4699) HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33; CD antigen CD74; CD74 nanobody	ELISA, FC	Human
	CD74 Antibody (YA4699) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD74. It can be applicated for ELISA, FC assays, in the background of human.

HY-P85898

	CD74 Antibody (YA5590) CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHLAG antibody; Gamma chain of class II antigens antibody; HG2A_HUMAN antibody; HLA class II histocompatibility antigen gamma chain antibody; HLA DR antigens associated invariant chain antibody; HLA DR gamma antibody; HLA-DR antigens-associated invariant chain antibody; HLA-DR-gamma antibody; HLADG antibody; HLADR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC HLA DR gamma chain antibody; MHC HLA-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody	IHC-P, WB, ICC/IF, ELISA	Human
	CD74 Antibody (YA5590) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD74. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150749A

ODN D-SL03 sodium		CpG ODNs
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150740A

ODN 21595 sodium		CpG ODNs
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595		CpG ODNs
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150749

ODN D-SL03		CpG ODNs
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.